Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system.
A(H1N1)pdm09 vaccine
AS03 adjuvant system
cross-reactivity
non-neutralizing antibodies
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
17
02
2020
revised:
12
06
2020
accepted:
18
06
2020
pubmed:
6
9
2020
medline:
26
11
2021
entrez:
5
9
2020
Statut:
ppublish
Résumé
Non-neutralizing antibodies inducing complement-dependent lysis (CDL) and antibody-dependent cell-mediated cytotoxicity (ADCC) activity may contribute to protection against influenza infection. We investigated CDL and ADCC responses in healthy adults randomized to receive either non-adjuvanted or AS03-adjuvanted monovalent A(H1N1)pdm09 vaccine (containing 15 µg/3.75 μg of hemagglutinin, respectively) on a 2-dose schedule 21 days apart. We conducted an exploratory analysis of a subset of 106 subjects having no prior history of A(H1N1)pdm09 infection or seasonal influenza vaccination enrolled in a previously reported study (NCT00985673). Antibody responses against the homologous A/California/7/2009 (H1N1) vaccine strain and a related A/Brisbane/59/2007 (H1N1) seasonal influenza strain were analyzed up to Day 42. Baseline seropositivity determined with hemagglutination inhibition (HI), CDL and ADCC antibody titers against viral strains was high; A/California/7/2009 (HI [40.4-48.1%]; CDL [34.6-36.0%]; ADCC [92.1-92.3%]); A/Brisbane/59/2007 (HI [73.1-88.9%]; CDL [38.0-42.0%]; ADCC [86.8-97.0%]). CDL seropositivity increased following vaccination with both adjuvanted and non-adjuvanted formulations (A/California/7/2009 [95.9-100%]; A/Brisbane/59/2007 [75.5-79.6%]). At Day 21, increases in CDL and ADCC antibody geometric mean titers against both strains were observed for both formulations. After 2 doses of AS03-adjuvanted vaccine, vaccine responses of 95.8% (≥9-fold increase from baseline in CDL titers) and 34.3% (≥16-fold increase from baseline in ADCC titers) were seen against A/California/7/2009; and 22.4% and 42.9%, respectively, against A/Brisbane/59/2007. Vaccine responses after 2 doses of the non-adjuvanted vaccine were broadly similar. Broadly comparable non-neutralizing immune responses were observed following vaccination with non-adjuvanted and AS03-adjuvanted A(H1N1)pdm09 formulations; including activity against a related vaccine strain.
Sections du résumé
BACKGROUND
Non-neutralizing antibodies inducing complement-dependent lysis (CDL) and antibody-dependent cell-mediated cytotoxicity (ADCC) activity may contribute to protection against influenza infection. We investigated CDL and ADCC responses in healthy adults randomized to receive either non-adjuvanted or AS03-adjuvanted monovalent A(H1N1)pdm09 vaccine (containing 15 µg/3.75 μg of hemagglutinin, respectively) on a 2-dose schedule 21 days apart.
METHODS
We conducted an exploratory analysis of a subset of 106 subjects having no prior history of A(H1N1)pdm09 infection or seasonal influenza vaccination enrolled in a previously reported study (NCT00985673). Antibody responses against the homologous A/California/7/2009 (H1N1) vaccine strain and a related A/Brisbane/59/2007 (H1N1) seasonal influenza strain were analyzed up to Day 42.
RESULTS
Baseline seropositivity determined with hemagglutination inhibition (HI), CDL and ADCC antibody titers against viral strains was high; A/California/7/2009 (HI [40.4-48.1%]; CDL [34.6-36.0%]; ADCC [92.1-92.3%]); A/Brisbane/59/2007 (HI [73.1-88.9%]; CDL [38.0-42.0%]; ADCC [86.8-97.0%]). CDL seropositivity increased following vaccination with both adjuvanted and non-adjuvanted formulations (A/California/7/2009 [95.9-100%]; A/Brisbane/59/2007 [75.5-79.6%]). At Day 21, increases in CDL and ADCC antibody geometric mean titers against both strains were observed for both formulations. After 2 doses of AS03-adjuvanted vaccine, vaccine responses of 95.8% (≥9-fold increase from baseline in CDL titers) and 34.3% (≥16-fold increase from baseline in ADCC titers) were seen against A/California/7/2009; and 22.4% and 42.9%, respectively, against A/Brisbane/59/2007. Vaccine responses after 2 doses of the non-adjuvanted vaccine were broadly similar.
CONCLUSIONS
Broadly comparable non-neutralizing immune responses were observed following vaccination with non-adjuvanted and AS03-adjuvanted A(H1N1)pdm09 formulations; including activity against a related vaccine strain.
Identifiants
pubmed: 32889792
doi: 10.1111/irv.12780
pmc: PMC7767944
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Viral
0
Influenza Vaccines
0
Polysorbates
0
Squalene
7QWM220FJH
Banques de données
ClinicalTrials.gov
['NCT00985673']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110-120Subventions
Organisme : Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority
ID : HHSO100200700029C
Informations de copyright
© 2020 Glaxosmithkline Biologicals. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
J Infect Dis. 2016 Sep 15;214(6):945-52
pubmed: 27354365
J Immunol. 2013 Feb 15;190(4):1837-48
pubmed: 23319732
Curr Opin Virol. 2017 Feb;22:89-96
pubmed: 28088123
Expert Rev Vaccines. 2017 Nov;16(11):1141-1154
pubmed: 28925296
J Infect Dis. 2017 Mar 1;215(5):818-823
pubmed: 28011910
J Immunol. 2014 Jul 15;193(2):469-75
pubmed: 24994909
Viral Immunol. 2014 Oct;27(8):375-82
pubmed: 25141276
J Infect Dis. 2015 Oct 1;212(7):1052-60
pubmed: 25795791
Vaccine. 2017 Jan 5;35(2):238-247
pubmed: 27914742
Clin Vaccine Immunol. 2011 May;18(5):835-43
pubmed: 21450978
Future Virol. 2015;10(9):1033-1047
pubmed: 26587050
Vaccine. 2018 Apr 12;36(16):2213-2219
pubmed: 29548607
Virus Res. 2011 Dec;162(1-2):19-30
pubmed: 21963677
Vaccine. 2019 May 21;37(23):3006-3021
pubmed: 31031030
J Pediatric Infect Dis Soc. 2018 Aug 17;7(3):178-180
pubmed: 29982613
Vaccine X. 2019 Jun 20;2:100029
pubmed: 31384744
J Infect Dis. 2013 Oct 1;208(7):1051-61
pubmed: 23812238
Vaccine. 2020 Feb 28;38(10):2368-2377
pubmed: 32035709
BMC Infect Dis. 2012 Oct 30;12:279
pubmed: 23110320
Hum Vaccin Immunother. 2012 Sep;8(9):1218-22
pubmed: 22894961
Viral Immunol. 2018 Mar;31(2):174-183
pubmed: 29373086
J Infect Dis. 1983 Nov;148(5):785-94
pubmed: 6605395
Influenza Other Respir Viruses. 2021 Jan;15(1):110-120
pubmed: 32889792
Clin Vaccine Immunol. 2017 Jun 5;24(6):
pubmed: 28446441
J Infect Dis. 2019 Sep 13;220(8):1276-1280
pubmed: 31169293
J Virol. 2011 Dec;85(24):13463-7
pubmed: 21994454